Compare RCUS & PBH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RCUS | PBH |
|---|---|---|
| Founded | 2015 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 2.8B |
| IPO Year | 2018 | 2005 |
| Metric | RCUS | PBH |
|---|---|---|
| Price | $21.31 | $61.73 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 5 |
| Target Price | $29.38 | ★ $86.40 |
| AVG Volume (30 Days) | ★ 2.1M | 439.1K |
| Earning Date | 10-28-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 4.04 |
| Revenue | $240,000,000.00 | ★ $1,110,479,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $2.50 |
| P/E Ratio | ★ N/A | $15.20 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.50 | $57.25 |
| 52 Week High | $26.40 | $90.04 |
| Indicator | RCUS | PBH |
|---|---|---|
| Relative Strength Index (RSI) | 41.72 | 56.85 |
| Support Level | $20.35 | $59.52 |
| Resistance Level | $26.10 | $62.14 |
| Average True Range (ATR) | 1.48 | 1.48 |
| MACD | -0.61 | 0.32 |
| Stochastic Oscillator | 15.21 | 83.84 |
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.
Prestige Consumer Healthcare is one of the largest pure-play over-the-counter healthcare providers. It has a diverse portfolio composed of leading brands in niche consumer health categories. Prestige's key brands include Clear Eyes (redness relief), Dramamine (motion sickness relief), Monistat (vaginal anti-fungal), and Summer's Eve (feminine hygiene), and many of its brands enjoy category leadership and recommendations from medical professionals. The firm mainly plays in North America where it generates roughly 85% of its total revenue, and the remaining sales come from Australia, New Zealand, and certain Asian markets.